

Steven P Marso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12104959/publications.pdf>

Version: 2024-02-01

123
papers

22,696
citations

38742

50
h-index

19190

118
g-index

126
all docs

126
docs citations

126
times ranked

15439
citing authors

#	ARTICLE	IF	CITATIONS
1	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.	27.0	5,070
2	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1834-1844.	27.0	3,898
3	A Prospective Natural-History Study of Coronary Atherosclerosis. <i>New England Journal of Medicine</i> , 2011, 364, 226-235.	27.0	2,721
4	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	27.0	1,455
5	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 839-848.	27.0	903
6	Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. <i>Journal of the American College of Cardiology</i> , 2001, 38, 409-414.	2.8	593
7	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	27.0	480
8	Peripheral Arterial Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2006, 47, 921-929.	2.8	430
9	Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. <i>American Journal of Cardiology</i> , 2002, 90, 625-628.	1.6	376
10	Glucometrics in Patients Hospitalized With Acute Myocardial Infarction. <i>Circulation</i> , 2008, 117, 1018-1027.	1.6	349
11	Abciximab reduces mortality in diabetics following percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2000, 35, 922-928.	2.8	312
12	Bleeding in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 222-229.	3.9	278
13	Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus. <i>Circulation</i> , 1999, 100, 2477-2484.	1.6	272
14	Association Between Use of Bleeding Avoidance Strategies and Risk of Periprocedural Bleeding Among Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2156.	7.4	264
15	Chronic Total Occlusion Angioplasty in the United States. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 479-486.	2.9	259
16	Association Between Bleeding Events and In-hospital Mortality After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1022.	7.4	235
17	Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1523-1534.	2.9	234
18	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 191-197.	2.9	229

#	ARTICLE	IF	CITATIONS
19	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal, 2013, 166, 823-830.e5.	2.7	182
20	Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury. Circulation, 2003, 107, 2238-2243.	1.6	168
21	Temporal Trends in and Factors Associated With Bleeding Complications Among Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 59, 1861-1869.	2.8	129
22	Improvement in Survival Following Successful Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions: Variability by Target Vessel. JACC: Cardiovascular Interventions, 2008, 1, 295-302.	2.9	126
23	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia, 2018, 61, 48-57.	6.3	126
24	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia, 2018, 61, 58-65.	6.3	124
25	Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes. JACC: Cardiovascular Imaging, 2012, 5, S42-S52.	5.3	113
26	Neointimal Hyperplasia After Arterial Injury Is Increased in a Rat Model of Non-Insulin-Dependent Diabetes Mellitus. Circulation, 2001, 104, 815-819.	1.6	107
27	Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies. Diabetes and Vascular Disease Research, 2011, 8, 237-240.	2.0	101
28	Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
29	Costs of Transradial Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 827-834.	2.9	96
30	Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 342-351.	2.9	92
31	Incidence, Correlates, and Outcomes of Acute, Hospital-Acquired Anemia in Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 337-346.	2.2	91
32	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes and Endocrinology, 2020, 8, 880-893.	11.4	86
33	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal, 2016, 174, 103-110.	2.7	82
34	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation, 2018, 138, 2884-2894.	1.6	82
35	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care, 2018, 41, 1783-1791.	8.6	82
36	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation, 2018, 137, 2179-2183.	1.6	80

#	ARTICLE	IF	CITATIONS
37	Intravascular ultrasound radiofrequency analysis of coronary atherosclerosis: an emerging technology for the assessment of vulnerable plaque. <i>European Heart Journal</i> , 2007, 28, 1283-1288.	2.2	69
38	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 376, 890-892.	27.0	69
39	Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 595-605.	11.4	61
40	The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1269-1277.	2.8	60
41	Diabetes Duration Is Associated With Increased Thin-Cap Fibroatheroma Detected by Intravascular Ultrasound With Virtual Histology. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 543-548.	3.9	59
42	Comparison of costs between transradial and transfemoral percutaneous coronary intervention: A cohort analysis from the Premier research database. <i>American Heart Journal</i> , 2013, 165, 303-309.e2.	2.7	58
43	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) <i>TJ ETQq1 1 0.784314 rgBT /Overlaid</i> <i>Journal</i> , 2016, 179, 175-183.	2.7	58
44	A Detailed Analysis of Perforations During Chronic Total Occlusion Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1902-1912.	2.9	58
45	Enhanced Efficacy of Eptifibatid Administration in Patients With Acute Coronary Syndrome Requiring In-Hospital Coronary Artery Bypass Grafting. <i>Circulation</i> , 2000, 102, 2952-2958.	1.6	56
46	Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 712-724.	2.9	56
47	LEADER 3â Lipase and Amylase Activity in Subjects With Type 2 Diabetes. <i>Pancreas</i> , 2014, 43, 1223-1231.	1.1	54
48	Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting. <i>Circulation</i> , 2002, 105, 322-327.	1.6	53
49	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1128-1141.	2.8	53
50	The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 119-130.	2.0	52
51	Procedural failure of chronic total occlusion percutaneous coronary intervention: Insights from a multicenter US registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 1115-1122.	1.7	52
52	Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. <i>Journal of the American Heart Association</i> , 2015, 4, e002137.	3.7	52
53	Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 197-205.	2.2	52
54	Quantifying Improvement in Symptoms, Functioning, and Quality of Life After Peripheral Endovascular Revascularization. <i>Circulation</i> , 2007, 115, 569-575.	1.6	50

#	ARTICLE	IF	CITATIONS
55	Percutaneous Coronary Intervention Use in the United States. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 229-235.	2.9	50
56	Low Adiponectin Levels Are Associated With Atherogenic Dyslipidemia and Lipid-Rich Plaque in Nondiabetic Coronary Arteries. <i>Diabetes Care</i> , 2008, 31, 989-994.	8.6	49
57	Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: An analysis of 25,223 patients over 20 years. <i>American Heart Journal</i> , 2003, 145, 270-277.	2.7	48
58	Impact of subintimal plaque modification procedures on health status after unsuccessful chronic total occlusion angioplasty. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1035-1042.	1.7	48
59	Management of Percutaneous Coronary Intervention Complications. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008962.	3.9	46
60	The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry. <i>Coronary Artery Disease</i> , 2017, 28, 110-119.	0.7	45
61	Management of Hyperglycemia with the Administration of Intravenous Exenatide to Patients in the Cardiac Intensive Care Unit. <i>Endocrine Practice</i> , 2013, 19, 81-90.	2.1	44
62	Percutaneous Intervention of Circumflex Chronic Total Occlusions Is Associated With Worse Procedural Outcomes: Insights From a Multicentre US Registry. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1588-1594.	1.7	44
63	Relation Between Angiographic Lesion Severity, Vulnerable Plaque Morphology and Future Adverse Cardiac Events (from the Providing Regional Observations to Study Predictors of Events in the) Tj ETQq1 1 0.7843 146rgBT /Overlock	1.7	44
64	Blood Transfusion During Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 811-819.	2.8	42
65	Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry. <i>European Heart Journal</i> , 2010, 31, 196-202.	2.2	37
66	Pre-Procedural Estimate of Individualized Bleeding Risk Impacts Physicians' Utilization of Bivalirudin During Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1847-1852.	2.8	37
67	Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. <i>American Heart Journal</i> , 2000, 139, 939-944.	2.7	36
68	Cost-Effectiveness of Targeting Patients Undergoing Percutaneous Coronary Intervention for Therapy With Bivalirudin Versus Heparin Monotherapy According to Predicted Risk of Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 358-365.	2.2	35
69	Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 451-458.	5.3	34
70	Comparison of Bivalirudin and Radial Access Across a Spectrum of Preprocedural Risk of Bleeding in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 347-353.	3.9	32
71	Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients With Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 614-621.	2.9	31
72	Success rates of percutaneous coronary intervention of chronic total occlusions and long-term survival in patients with diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 45-51.	2.0	29

#	ARTICLE	IF	CITATIONS
73	Outcomes of 1,090 Consecutive, Elective, Nonselected Percutaneous Coronary Interventions at a Community Hospital Without Onsite Cardiac Surgery. <i>American Journal of Cardiology</i> , 2008, 101, 53-57.	1.6	29
74	Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007558.	3.9	29
75	Predictors of Plaque Rupture Within Nonculprit Fibroatheromas in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1180-1187.	5.3	28
76	Intravascular ultrasound measures of coronary atherosclerosis are associated with the Framingham risk score: an analysis from a global IVUS registry. <i>EuroIntervention</i> , 2009, 5, 212-218.	3.2	27
77	Optimizing the diabetic formulary: beyond aspirin and insulin. <i>Journal of the American College of Cardiology</i> , 2002, 40, 652-661.	2.8	26
78	Limitations to the use of virtual histology-intravascular ultrasound to detect vulnerable plaque. <i>European Heart Journal</i> , 2007, 28, 1783-1784.	2.2	25
79	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). <i>American Journal of Cardiology</i> , 2018, 121, 1467-1470.	1.6	25
80	Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits. <i>Vascular Medicine</i> , 2011, 16, 260-266.	1.5	24
81	Relationship Between Palpography and Virtual Histology in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S19-S27.	5.3	23
82	Characteristics and Clinical Significance of Angiographically Mild Lesions in Acute Coronary Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S86-S94.	5.3	23
83	Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 465-468.	2.0	22
84	Tissue characterisation of atherosclerotic plaque in the left main: an in vivo intravascular ultrasound radiofrequency data analysis. <i>EuroIntervention</i> , 2011, 7, 347-352.	3.2	20
85	Diabetes mellitus is associated with plaque classified as thin cap fibroatheroma: an intravascular ultrasound study. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 14-19.	2.0	19
86	Influence of Total Coronary Occlusion on Clinical Outcomes (from the Bypass Angioplasty) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td	1.6	19
87	Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN-CTO registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1162-1173.	1.7	19
88	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1625-1633.	4.4	18
89	Myonecrosis following isolated coronary artery bypass grafting is common and associated with an increased risk of long-term mortality. <i>European Heart Journal</i> , 2003, 24, 1323-1328.	2.2	17
90	The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 771-779.	2.9	17

#	ARTICLE	IF	CITATIONS
91	State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 4.	2.0	16
92	Usefulness of Coronary Atheroma Burden to Predict Cardiovascular Events in Patients Presenting With Acute Coronary Syndromes (from the PROSPECT Study). <i>American Journal of Cardiology</i> , 2015, 116, 1672-1677.	1.6	16
93	Comparison of Bleeding Complications Using Arterial Closure Device Versus Manual Compression by Propensity Matching in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2011, 107, 1619-1623.	1.6	12
94	Suspected Acute Coronary Syndrome Patients With Diabetes and Normal Troponin-I Levels Are at Risk for Early and Late Death: Identification of a new high-risk acute coronary syndrome population. <i>Diabetes Care</i> , 2006, 29, 1931-1932.	8.6	11
95	Compensatory enlargement of the left main coronary artery. <i>Coronary Artery Disease</i> , 2014, 25, 98-103.	0.7	11
96	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-bolus Regimens for Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , 2018, 9, 1217-1232.	2.5	11
97	Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2241-2247.	4.4	11
98	Acute Coronary Syndrome in the Patient with Diabetes: Is the Management Different?. <i>Current Cardiology Reports</i> , 2010, 12, 321-329.	2.9	10
99	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). <i>Applied Health Economics and Health Policy</i> , 2019, 17, 615-627.	2.1	10
100	LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 37.	2.7	9
101	Association between health status and long-term mortality after percutaneous revascularization of peripheral artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1149-1155.	1.7	9
102	Metabolic syndrome-mediated inflammation following elective percutaneous coronary intervention. <i>Diabetes and Vascular Disease Research</i> , 2005, 2, 31-36.	2.0	8
103	Stratification of risk in thin cap fibroatheromas using peak plaque stress estimates from idealized finite element models. <i>Medical Engineering and Physics</i> , 2012, 34, 1330-1338.	1.7	8
104	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2248-2256.	4.4	8
105	Coronary Revascularization Strategies in Patients With Diabetes and Multivessel Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1198-1201.	2.8	7
106	Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2018, 9, 551-564.	2.5	7
107	Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome. <i>Diabetes and Vascular Disease Research</i> , 2005, 2, 128-135.	2.0	6
108	Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study. <i>American Heart Journal</i> , 2012, 164, 561-567.	2.7	6

#	ARTICLE	IF	CITATIONS
109	Improving in-hospital mortality in the setting of an increasing risk profile among patients undergoing catheter-based reperfusion for an acute myocardial infarction without cardiogenic shock. Journal of Invasive Cardiology, 2003, 15, 711-6.	0.4	6
110	Inpatient or Outpatient Status for Elective Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003699.	3.9	5
111	Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 1994-1996.	27.0	5
112	Revascularization Approaches. , 2018, , 337-354.		4
113	Revascularization Trumps Medicine for Patients With Type 2 Diabetes Mellitus and Chronic Angina (or) Tj ETQq1 1 0.784314,ggBT /Over	1.6	3
114	Relationship between left main coronary artery plaque burden and nonleft main coronary atherosclerosis. Coronary Artery Disease, 2018, 29, 397-402.	0.7	3
115	Review: The pathogenesis of type 2 diabetes and cardiovascular disease. British Journal of Diabetes and Vascular Disease, 2002, 2, 350-356.	0.6	2
116	Diabetes and Percutaneous Coronary Revascularization in the Drug-Eluting Stent Era. Herz, 2004, 29, 542-50.	1.1	1
117	Diabetes mellitus and vascular risk: continuing the quest for the elusive keystone. Diabetes and Vascular Disease Research, 2005, 2, 7-8.	2.0	1
118	Comparison of Procedural Complications With Versus Without Interventional Cardiology Fellows-in-Training During Contemporary Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 44-48.	1.6	1
119	How to Fix Common Problems Encountered in CTO PCI: The Expanded Hybrid Approach. , 2016, , 141-159.		1
120	Is a high hematocrit level good for patients with heart failure?. Journal of the American College of Cardiology, 2002, 39, 1703-1704.	2.8	0
121	Plaque Burden With Composition?. Journal of the American College of Cardiology, 2010, 55, 983-985.	2.8	0
122	Treating Leave Behind Lesions. Circulation: Cardiovascular Interventions, 2018, 11, e007367.	3.9	0
123	Improving the pharmacological regimen for patients with diabetes mellitus. Reviews in Cardiovascular Medicine, 2004, 5, 139-47.	1.4	0